Skip to main content

Table 1 Ongoing clinical trials evaluating the available systemic treatments in lung carcinoids

From: Systemic treatment for lung carcinoids: from bench to bedside

Systemic treatment Study identifier Study title Study design Population Intervention Primary endpoint
SSAs NCT02683941 SPINET Phase 3
Randomized double-blind
TCs and ACs Lanreotide + BSC vs PCB + BSC DCR
NCT02698410 ATLANT Phase 2
Single arm
Open-label
TCs and ACs Lanreotide + TMZ PFS
NCT02823691 MetNET-2 Early Phase 1 Advanced GI-NENs and lung carcinoids Lanreotide + metformin Safety
PRRT NCT03466216 Phase 1 SSTRs positive advanced NENs AlphaMedix™ Safety and DLT
NCT03273712 Phase 2
Single arm Open-label
SSTRs positive advanced NENs [Yttrium-90-DOTA]TOC ORR and safety
NCT03454763 LUTHREE Phase 2
Randomized
Open-label
SSTRs positive advanced NENs [Lutetium-177-DOTA]TATE every 5 week (intensive) vs Lutetium-177-DOTA]TATE every 8–10 week (no intensive) PFS and safety
NCT02754297 P-PRRT Phase 2
Single arm
Open-label
SSTRs positive advanced NENs [Lutetium-177-DOTA]TOC ORR
Everolimus NCT03629847 Phase 1–2
Single arm
Open-label
SSTRs positive advanced NENs Everolimus + [Lutetium-177-DOTA]TATE Safety
NCT03670030 Phase 2
Single arm
Open-label
Advanced well differentiated NENs ABI-009 ORR
CHT NCT02698410 ATLANT Phase 2
Single arm
Open-label
TCs and ACs Lanreotide + temozolomide DCR
NCT03217097 MGMT-NET Phase 4
Randomized
Open-label
Advanced well differentiated lung, duodenopancreatic and unknown origin NENs Oxaliplatin vs temozolomide ORR
  1. TCs typical carcinoids, ACs atypical carcinoids, PCB placebo, BSC best supportive care, TMZ temozolomide, DCR disease control rate, PFS progression free survival, GI gastrointestinal, SSTRs somatostatin receptors, ORR objective response rate, CHT chemotherapy